Cognis completes Napro buy, speeds integration

By staff reporter

- Last updated on GMT

Related tags: Cognis, Omega-3 fatty acid

Cognis has completed its acquisition of Norwegian fish oil provider
Napro Pharma, and is now integrating it into its operations to be
able to offer omega-3 as soon as possible.

The German group announced plans to buy Napro in May and said that it is developing new solutions to aid the use of its omega-3 oils in foods.

The financial details of the transaction have not been disclosed.

"Now that the ink is dry we are working diligently to fully integrate omega-3s into Cognis' product mix so we can effectively address the strong interest expressed by customers and prospects,"​ said Dave Eckert, VP of Cognis Nutrition & Health.

Eckert said that the Napro integration is a high priority, given the demand for omega-3.

Market research indicates that the global marine oil market is set to grow at a rate of 13 per cent per annum to be worth $993m in 2010. The predicted EU growth rate is 6 per cent per annum. Concentrates, such as Napro's ethyl ester and triglyceride forms, are said to lead the category.

Cognis has said that the buy is the next step in its corporate strategy to grow in step with new health trends. Especially in light of research into their heart health benefits, omega-3s seen as a perfect complement to Cognis' existing offerings in the health arena, which include cholesterol-lowering Vegapure plant sterols and sterol esters.

Related news

Show more

Related products

show more

Does my Nutraceutical Need a Clinical Trial?

Does my Nutraceutical Need a Clinical Trial?

dicentra – CRO and regulatory consulting firm | 03-Aug-2020 | Technical / White Paper

The global nutraceutical industry is growing at an unprecedented rate. However, companies preparing to bring new and innovative products to the burgeoning...

Supporting cardiovascular health with probiotics

Supporting cardiovascular health with probiotics

Deerland Probiotics & Enzymes | 03-Aug-2020 | Technical / White Paper

Throughout the last decade, researchers have investigated the role of the gut microbiota in the development of cardiovascular disease. Evidence exists...

Related suppliers

Follow us


View more